07 December 2011, Uppsala, Sweden: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Binex Co., Ltd., a leading CDMO (Contract Development & Manufacturing Organization) for biotechnology products in the Asian-Pacific region, has purchased a Gyrolab™ workstation.
S.E. Kim, president and CEO at DI Biotech, the sole distributor of Gyros products in South Korea, commented: “We are extremely pleased that Binex has become the first South Korean customer to adopt this exciting new platform. Our goal at DIBiotech is to ensure that our customers have access to the latest ground-breaking technologies. We firmly believe that the Gyros platform, will not only increase productivity, but also boost the competitiveness of South Korea’s pharma and biotech companies as well as our CROs and CMOs.”
The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, to boost time-critical workflows and help meet regulatory demands. The platform comprises a Gyrolab workstation, control and evaluation software and the unique microfluidic CDs in which immunoassay steps are integrated and run at nanoliter scale.
Erik Walldén, CEO at Gyros, continued, “We have been actively expanding our distributor network throughout the Asia-Pacific region and see this as a significant step on the way to establishing a global presence for our immunoassay platform.”
About Gyros AB www.gyros.com
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.
Enquiries:
Katie Odgaard
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947
Skype: kodgaard
Email: katie.odgaard@zymecommunications.com
www.zymecommunications.com
Binex enquiries:
Jeong Hwa Son, Ph.D.
Binex Co., Ltd.
Songdo-dong 7-48, Incheon IFEZ, South Korea 406-840
Tel: +82-32-850-3121
Fax: +82-32-850-3128
Email: sjhwa@bi-nex.com
www.bi-nex.com
